BRIEF—Albireo's Bylvay gains reimbursed access in France

Boston, USA-based rare diseases specialist Albireo Pharma is set to further roll-out its Bylvay (odevixibat) as the Committee Economic Health Products (CEPS) has approved reimbursed access to the drug in France following a favorable clinical assessment from the Haute Autorité de Santé (HAS) for the treatment of progressive familial intrahepatic cholestasis (PFIC) types 1 and 2 (except for the BSEP3 subtype).

A potent, oral, once-daily, non-systemic ileal bile acid transport inhibitor, Bylvay has minimal systemic exposure and acts locally in the small intestine as a treatment for PFIC, a rare and devastating disorder that affects young children and causes progressive, life-threatening liver disease.

This availability marks the sixth reimbursement approval for Bylvay in Europe, following launches in Germany, the UK (NICE and SMC), Italy, and Belgium.